Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer. Strong support from leading investors and global pharma partners continues to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a Phase 3-ready neuro-physiology company developing a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback